Brief: Cure Pharma says Oak Therapeutics completes milestone in phase 1 of NIH grant
22/08/2017 14:00
Aug 22 (Reuters) - Cure Pharmaceutical Holding Corp
CURR.PK :
* Oak Therapeutics completed critical milestone in phase 1
of NIH grant to develop oral dissolvable strip for tuberculosis
* Unit Oak Therapeutics is currently in the application
process for phase II of the SBIR program
Further company coverage: CURR.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Avenir Wellness Solutions
See all newsBrief: Cure Pharmaceutical Reports Q2 2022 Results
Brief: Cure Pharmaceutical Announces Rob Davidson As New Chairman Of The Board And Appointment Of Rob Costantino As Member Of The Board And Audit Committee Chairman
Brief: Cure Pharmaceutical Holding Q1 Revenue $1.5 Million
Brief: CURE Pharmaceutical Augments Its Existing U.S. DEA License
Brief: Cure Pharmaceutical Receives FDA Approval For Its IND Application For Curefilm Blue